Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058262 | 0.86 | ALDH1A1 (0.58) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL18765958 | 0.85 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL4559946 | 0.85 | HPGD (0.58) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL11931984 | 0.85 | ATM (0.58) | ALDH1A1GLATSHRHTTSMN1; SMN2 | |
| SCHEMBL13741509 | 0.85 | ATM (0.58) | ALDH1A1GLATSHRHTTSMN1; SMN2 | |
| SCHEMBL4061019 | 0.83 | ALDH1A1 (0.54) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL1114963 | 0.83 | ALDH1A1 (0.54) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL12679897 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL7497334 | 0.82 | ALDH1A1 (0.61) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL11618038 | 0.82 | ALDH1A1 (0.61) | ALDH1A1GLATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046560-A1 | STEM CELL MODULATION II | University of Canberra (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039187-A1 | STEM CELL MODULATION II | UNIVERSITY OF CANBERRA (AU) | 2015-03-26 | — | — | WO | disclosed |
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | ALDH1A1 3943/4885GLA 2333/4885TSHR 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.